Deuterated Reagents for Pharmaceuticals
In recent years, some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring.
Stable Isotope-Labeled Synthetic Intermediates
The potential advantages of deuterated pharmaceuticals includes:
Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.
Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track, allowing more of the unmetabolized drug to reach its target.
Increased half-life. Deuterated compounds can have a slower pharamacokinetic affect, extending the absorption and distribution in the body. This may decrease the number of doses a patient may require in certain time period compared to its nondeuterated counterpart.
| Catalog No. | Description |
| DLM-112 | Acetaldehyde-d (D, 99%) |
| DLM-12RG* | Acetic acid-d4 (D, 99%) |
| DLM-1556 | Acetic acid-d (D, 98%) |
| DLM-1162 | Acetic anhydride-d6 (D, 98%) |
| DLM-9RG* | Acetone-d6 (D, 99.5%) |
| DLM-247 | Acetyl chloride-d3 (D, 98%) |
| DLM-855 | Acrylic-2,3,3,-d3 acid (+ 0.1% 4-methoxyphenol) (D, 98%) (<5% H2O) |
| DLM-710RG |
Ammonium deuteroxide-d5 (D, 99%) (~25% Sol. In D2O)
|
| DLM-862 | Aniline-ring-d5, (D, 98%) |
| DLM-1RG* | Benzene-d6 (D, 99%) |
| DLM-494 | Biphenyl- d10 (D, 98%) |
| DLM-1315 | Borane-d3, (D, 98%) (1 molar in THF) (+0.005M NaBD4) |
| DLM-4747 | Borane-d3 methylsulfide complex (D, 98%) (contains <10% additional dimethylsulfide) |
| DLM-398 | Bromobenzene-d5, (D, 99%) |
| DLM-874 | Bromoethane-d5, (D, 98%) |
| DLM-181 | 1,4-Butanediol-2,2,3,3-d4 (D, 98%) |
| DLM-1664 | tert-Butanol-d10, (D, 98%) |
| DLM-1116 | tert-Butyl chloride-d9 (D, 98%) |
| DLM-263 | Chlorobenzene-d5 (D, 99%) |
| DLM-337 | Chlorobenzene-d3 (D, 99%) |
| DLM-7RG | Chloroform-d (D, 99.7%) |
| DLM-1560 | Cyclohexanone-d10 (D, 98%) |
| DLM-2781 | Cyclopentyl bromide-d9 (D, 98%) |
| DLM-1003DR | Deuterium (D, 99.96) <400 ppm HD |
| DLM-408DR | Deuterium (D, 99.8%) (D2, 99.6% + HD, 0.4%) |
| DLM-458DR | Deuterium chloride (D, 99%) |
| DLM-3DR | Deuterium chloride (D, 99.5%) DCl 35% w/w solution in D2O |
| DLM-2 | Deuterium chloride (D, 99.5%) DCl 20% w/w solution in D2O |
| DLM-4DR | Deuterium oxide (D, 99.9%) |
| DLM-4DR-99.8 | Deuterium oxide (D, 99.8%) |
| DLM-195 | 1,2-Dibromoethane-d4 (D, 99%) |
| DLM-158 | 1,2-Dichlorobenzene-d4 (D, 99%) |
| DLM-265 |
Dimethyl-d6-amine:HCI (D,98%)
|
| DLM-3903 | Dimethyl carbonate-d6 (D, 99%) |
| DLM-196 | Dimethyl sulfate-d6, (D, 98%) |
| DLM-10RG* | Dimethyl sulfoxide-d6 (D, 99.9%) |
| DLM-25 | N,N-Dimethylformamide-d7 (D, 99.5%) |
| DLM-1670 | N,N Dimethylformamide (formyl-D, 98-99%) |
| DLM-31 | Ethanol-d6 (D, 99%) anhydrous |
| DLM-16 | Ethanol-OD (D, 99%) <6% D2O |
| DLM-9660 | N-Ethylaniline-d10 (D, 98%) |
| DLM-9626 | N-Ethyl-d5-aniline (D, 98%) |
| DLM-347 | Ethylene-d4 (D, 98%) |
| DLM-805 | Formaldehyde-d2 (D, 98%) (~20% w/w in D2O) |
| DLM-286 | Formic acid-d2 (D, 98%) (<5% D2O) |
| DLM-743 | Formic acid (formyl-D, 98%) (<5% H2O) |
| DLM-423 | n-Heptane-d16 (D, 98%) |
| DLM-1023 | Iodoethane-1,1-d2 (D, 98%) + copper wire |
| DLM-1024 | Iodoethane-2,2,2-d3 (D, 98%) + copper wire |
| DLM-272 | Iodoethane-d5 (D, 99%) + copper wire |
| DLM-44 | Isopropanol-d8 (D, 99%) |
| DLM-6201 | a-Ketoglutaric acid-3,3,4,4-d4 (D, 98%) CP 90 |
| DLM-1945 | bis(2-Chloroethoxy)-d8-methane (D, 98%) |
| DLM-1981 | Methanesulfonic acid-d4 (D, 97-98%) |
| DLM-24RG* | Methanol-d4 (D, 99.5%) |
| DLM-15 | Methanol-OD (D, 99%) |
| DLM-10186 |
METHYLBORONIC ACID (METHYL-D3, 98%) > 90% CP
|
| DLM-651 | Methyl formate (formyl-D, 99%) |
| DLM-362 | Methyl iodide-d3 (D, 99.5%) + copper wire |
| DLM-9707 | Methyl-d3 methanesulfonate (D, 98%) |
| DLM-1500DR | Methyl-d3-amine (D, 98%) |
| DLM-289 | Methyl-d3-amine·HCl (D, 98%) |
| DLM-23RG | Methylene chloride-d2 (D,99.8%) |
| DLM-3484 | Morpholine-2,2,3,3,5,5,6,6-D8 (D, 98%) |
| DLM-295 | 2-Nitrophenol-ring-d4 (D, 98%) |
| DLM-296 | 4-Nitrophenol-ring-d4 (D,98%) |
| DLM-619 | Octanoic acid-d15 (D, 98%) |
| DLM-300 | Paraformaldehyde-d2 (D, 99%) |
| DLM-370 | Phenol-d6 (D, 98%) |
| DLM-788 | Phthalic anhydride-d4 (D, 98%) |
| DLM-9813 | Pivalic acid-trimethyl-d9, (D, 98%) |
| DLM-9662 | Pyrrolidine-2,2,3,3,4,4,5,5-d8 (D, 98%) |
| DLM-3078DR | N-Propanol-d7 (D, 98%) |
| DLM-226 | Sodium borodeuteride-d4 (D, 99%) CP 90-95% |
| DLM-45DR | Sodium deuteroxide (D, 99.5%) 40% in D2O |
| DLM-1361 | Sodium formate (D, 98%) |
| DLM-8206 | Sodium 2,2-dimethyl-2silapentane-5-sulfonate-d6 (DSS) (D, 98%) |
| DLM-33DR | Sulfuric acid-d2 (D, 99%) 96-98% in D2O |
| DLM-36 | Tetrahydrofuran-d8 (D, 99.5%) |
| DLM-2729 | Tetramethylsilane-d12 (D, 98%) |
| DLM-5RG* | Toluene-d8,(D, 99.5%) |
| DLM-46RG* |
Trifluoroacetic acid-d (D. 98%)
|
*Reagent grade
CP = chemical purity
References
Faleb, E.; Ulanenko, K.; et. al 2017. A Highly Efficient Suzuki-Miyaura Methylation of Pyridines Leading to the Drug Pirfenidone and to its CD3 Version (SD-560), Green Chemistry Read article
Hamilton, P. 2017. Deuterated drugs are new chemical entities. JDSUPRA® Read article
Mullard, A, 2016 Deuterated drugs draw heavier backing. Nature Reviews Drug Discovery, Published online 1 Apr 2016 PMID: 27032821
2015. Drugs that live long will prosper. The Economist, Science & Technology, Sept. 5 edition. economist.com. Read article
Technical Product Information
